Abstract
ᅟThe annual survey of The Japanese Society for Dialysis Therapy Renal Data Registry (JRDR) was conducted for 4396 dialysis facilities at the end of 2016, among which 4336 facilities (98.6%) responded. The response rate of the 2016 survey was comparable with the past, even though it was the second year after the new anonymization method. The number of chronic dialysis patients in Japan continues to increase every year; it has reached 329,609 at the end of 2016. The mean age was 68.15 years. The prevalence rate was 2597 patients per million population. Diabetic nephropathy was the most common primary disease among the prevalent dialysis patients (38.8%), followed by chronic glomerulonephritis (28.8%) and nephrosclerosis (9.9%). The rate of diabetic nephropathy and nephrosclerosis has been increasing year by year, whereas that of chronic glomerulonephritis was declining. The number of incident dialysis patients during 2016 was 39,344; it has remained stable since 2008. The average age was 69.40 years, and diabetic nephropathy (43.2%) was the most common cause in the incident dialysis patients. These patients caused by diabetes did not change in number for recent several years. Thirty-one thousand six hundred eight patients died in 2016; the crude mortality rate was 9.7%. The patients treated by hemodiafiltration (HDF) have been increasing rapidly from the revision of medical reimbursement for HDF therapy in 2012. It has attained 76,836 patients at the end of 2016, which were 21,503 greater than that in 2015. The number of peritoneal dialysis (PD) patients was 9021 in 2016, which had been slightly decreasing since 2014; 20.3% of PD patients treated in the combination of hemodialysis (HD) or HDF therapy. Six hundred thirty-five patients were treated by home HD therapy at the end of 2016; it increased by 63 from 2015.Trial registrationJRDR was approved by the ethical committee of JSDT and has been registered in “University hospital Medical Information Network (UMIN) Clinical Trials Registry” as an approved number of UMIN000018641 on August 8, 2015.
Highlights
The Japanese Society for Dialysis Therapy (JSDT) has been conducting a survey on the status of chronic dialysis therapy in Japan at the end of every year since 1968; this survey, known as the JSDT Renal Data Registry (JRDR), covers almost all dialysis facilities throughoutJapanese Society for Dialysis Therapy Renal Data Registry Committee, Japanese Society for Dialysis Therapy, Tokyo, JapanDepartment Nephrology, Honcho Yabuki Clinic, 1-6-17 Honcho, Yamagata, Yamagata 990-0043, Japan the country [1, 2]
Until the 2013 JRDR results were reported, there were two types of JRDR reports: prompt data of collected results reported at the annual meeting of the JSDT held every June and defined data subjected to subsequent data cleaning
Until the 2013 edition, the JRDR annual report was published in Japanese in every January issue of the Journal of the Japanese Society for Dialysis Therapy, and a translated version was published in Therapeutic Apheresis and Dialysis (TAD)
Summary
The Japanese Society for Dialysis Therapy (JSDT) has been conducting a survey on the status of chronic dialysis therapy in Japan at the end of every year since 1968; this survey, known as the JSDT Renal Data Registry (JRDR), covers almost all dialysis facilities throughout. A status report for the second preceding year was prepared from the defined (fixed) data and published every January in Journal of the Japanese Society for Dialysis Therapy. The JSDT has changed its survey methods based on these guidelines; starting with the 2015 JRDR, anonymity has been enhanced to ensure the protection of personal information. For the 2016 JRDR, USB flash drives containing facility surveys and patient surveys (the latter of which contained anonymized patient information) prepared in Excel were mailed to dialysis facilities throughout Japan in December 2016. All survey items used until 2016 are included in the members-only pages of the JSDT website (http://www.jsdt.or.jp/)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
